Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Research analysts at Svb Leerink issued their Q1 2020 EPS estimates for Aurinia Pharmaceuticals in a note issued to investors on Wednesday, August 7th. Svb Leerink analyst J. Schwartz forecasts that the company will post earnings of ($0.32) per share for the quarter. Svb Leerink also issued estimates for Aurinia Pharmaceuticals’ Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.36) EPS and Q4 2020 earnings at ($0.40) EPS.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported C($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of C($0.20) by C($0.03). The company had revenue of C$0.04 million during the quarter, compared to analysts’ expectations of C$0.07 million.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
See Also: Hold Rating
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.